超级家族II螺旋酶:对心血管疾病的潜在治疗点
Tianxiang Fang1,2,3,4, Xizhi Wang5, Ning Huangfu2,3,4
1Health Science Center, Ningbo University, Ningbo, China.
Frontiers in cardiovascular medicine
|December 28, 2023
概括
超级II (SFII) 酶是参与核酸代谢的关键酶. 本综述探讨了它们在心血管疾病 (CVD) 中的作用,确定了对诸如动脉样硬化和心力衰竭等疾病的潜在治疗点.
科学领域:
- 生物化学和分子生物学
- 心脏病学 心脏病学
- 遗传学 是一个遗传学.
背景情况:
- 心血管疾病 (CVD) 仍然是全球死亡的主要原因.
- 酶是核酸代谢中至关重要的酶,影响基因表达,炎症和脂质代谢.
- 异常的螺旋酶活性与各种人类疾病有关,包括癌症和免疫系统疾病.
研究的目的:
- 在心血管疾病的发病过程中全面审查II超级家族 (SFII) 基酶的调控机制.
- 要突出SFII螺旋酶在特定心血管疾病 (如动脉样硬化,心肌梗塞,心肌病和心力衰竭) 中的参与.
- 确定SFII螺旋体作为CVD的潜在治疗点.
主要方法:
- 文献综述,重点关注SFII螺旋酶在心血管疾病中的作用.
- 分析研究的分析研究的分子机制的SFII酶调节在心血管疾病.
- 综合现有证据,将SFII酶功能与心血管病理联系起来.
主要成果:
- SFII螺旋酶在各种心血管疾病背后的分子通路中发挥着重要作用.
- 特定的SFII螺旋酶的失调与动脉样硬化,心肌梗塞,心肌病和心力衰竭的发展和进展有关.
- 了解SFII螺旋酶功能为心血管疾病的新型治疗策略提供了洞察力.
结论:
- SFII螺旋酶是心血管健康和疾病的关键参与者.
- 准SFII螺旋酶通路为新型心血管疾病治疗提供了一个有希望的途径.
- 对SFII螺旋酶机制的进一步研究可以改善心血管疾病患者的治疗结果.
相关概念视频
00:55DNA Helicases
21.3K
DNA unwinding helicase enzymes are a type of motor protein. Motor proteins can translocate along filaments or polymers using energy generated from ATP hydrolysis. Helicases are involved in all the important cellular processes where DNA unwinding is required, such as DNA replication, repair, recombination, and transcription. They are present in all living organisms, but vary in their structure, function, and mechanism of action. For example, in prokaryotes, DnaB helicase binds and translocates...
21.3K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.9K
01:46Electron Transport Chain: Complex I and II
13.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.5K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
746
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
746
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
433
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
433